Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 68 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TT Clear all
Completed Phase 3 Interventional Results available

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

NCT00083551
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Oct 20, 2026, 5:38 PM EDT
Not listed Phase 2 Interventional

Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors

NCT00178698
View directory record Official record
Conditions
Neuroendocrine Cancer, Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Gastric Cancer
Interventions
thermochemotherapy, Cisplatin, Gemcitabine, Interferon-a
Other · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2011 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

NCT01978093
View directory record Official record
Conditions
Neisseria Meningitidis, Haemophilus Influenzae Type b
Interventions
Hib-MenCY-TT (MenHibrix®), Pediarix®, Rotarix®, Prevnar 13®, PedvaxHIB®, Havrix®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
26
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 20, 2026, 5:38 PM EDT
Terminated Phase 2 Interventional Results available

Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation

NCT02700841
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Melphalan, Peripheral Blood Stem Cell Transplantation--CD34 HSCT, Peripheral Blood Stem Cell Transplantation--AHSCT, T Cell-Depleted Hematopoietic Stem Cell Transplantation, Tetanus Toxoid Vaccine
Drug · Procedure · Biological
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

NCT00345579
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
4,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
61
States / cities
Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Early Phase 1 Interventional

HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas

NCT00874861
View directory record Official record
Conditions
Astrocytoma, Oligoastrocytoma, Oligodendroglioma
Interventions
Peptide vaccine + Poly-ICLC
Biological
Lead sponsor
Ian F. Pollack, M.D.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Not applicable Interventional

VR-treadmill Combined Intervention for Enhancing Mobility and Cognitive Function in Patients With Multiple Sclerosis

NCT02427997
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Treadmill training with Virtual Reality, Treadmill training
Behavioral
Lead sponsor
Tel-Aviv Sourasky Medical Center
Government
Eligibility
18 Years to 65 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Oct 20, 2026, 5:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epigenomic and Metabolomic Signatures of APOA2 Gene by Saturated Fat Interaction

NCT03452787
View directory record Official record
Conditions
Body Mass Index
Interventions
None, cohort studies
Other
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 90 Years
Enrollment
602 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2018 · Synced Oct 20, 2026, 5:38 PM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Tocotrienols for Skeletal Muscle Health

NCT03708354
View directory record Official record
Conditions
Dynapenia, Postmenopausal Women
Interventions
placebo softgel, DeltaGold® Tocotrienol 70%
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
60 Years to 85 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Not applicable Interventional Results available

Identification of TT Cases by Community Treatment Assistants: An Assessment

NCT01783743
View directory record Official record
Conditions
Trichiasis
Interventions
TT Training Program and TT Screening Card
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
15 Years and older
Enrollment
27,473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 20, 2026, 5:38 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Non-Invasive Spinal Cord Stimulation After Injury

NCT03998527
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Transcutaneous Electrical Spinal Cord Stimulation (TcESCS)
Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2029
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed No phase listed Observational

TT-CMV Observational Birth Cohort Study

NCT00907686
View directory record Official record
Conditions
Cytomegalovirus Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
1 Hour to 5 Days
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

NCT00289783
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine, ActHIB, PedvaxHIB, Pediarix, Prevnar, M-M-R II, Varivax
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 15 Months
Enrollment
4,441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Not applicable Interventional

Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

NCT07630402
View directory record Official record
Conditions
Breast Cancer With Low to Intermediate HER2 Expression
Interventions
Echocardiogram
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Not yet recruiting Phase 1 Interventional

PHASE 1 TRIAL OF Lm-LLO-TT AND GEMCITABINE IN UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA

NCT07828236
View directory record Official record
Conditions
Pancreas Cancer, Duct Cell Adenocarcinoma, Pancreatic Cancer, Advanced Pancreatic Adenocarcinoma
Interventions
Lm-LLO-TT
Biological
Lead sponsor
Loki Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Not applicable Interventional

Teletherapy in Children Who Are Deaf and Hard of Hearing

NCT04928209
View directory record Official record
Conditions
Hearing Loss, Speech and Language Development Delay Due to Hearing Loss
Interventions
Speech-Language Teletherapy
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
0 Months to 27 Months
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Oakland, California • Palo Alto, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Entolimod, an Adjuvant for Vaccine Augmentation

NCT03063736
View directory record Official record
Conditions
Substance Use Disorders
Interventions
Entolimod, Td Vaccine
Drug · Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Carbohydrates and Running Performance

NCT06742398
View directory record Official record
Conditions
Nutrition, Healthy
Interventions
Carbohydrate Dissolvable Strip, Carbohydrate Mouth Rinse, Water Mouth Rinse
Other
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder

NCT02354703
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 20, 2026, 5:38 PM EDT
Completed No phase listed Observational

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

NCT05611229
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Nivolumab, Pembrolizumab, Dabrafenib+Trametinib, Ipilimumab+Nivolumab, Vemurafenib+Cobimetinib, Encorafenib+Binimetinib
Drug · Combination Product
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention

NCT01661764
View directory record Official record
Conditions
Colorectal Adenomatous Polyps
Interventions
Eicosapentanoic acid and docosahexanoic acid, Oleic Acid
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
40 Years to 79 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 20, 2026, 5:38 PM EDT
Completed No phase listed Observational

Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients

NCT05984615
View directory record Official record
Conditions
BRAF Positive Metastatic Melanoma
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Role of Polyunsaturated Fatty Acids (PUFA)-Gene Interactions in Heath Disparities

NCT02962128
View directory record Official record
Conditions
Fatty Acid-Gene Interactions
Interventions
High Linoleic Acid (LA) Diet, Low Linoleic Acid (LA) Diet
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

NCT02960230
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
K27M peptide, Nivolumab
Biological · Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
3 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
14
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 20, 2026, 5:38 PM EDT